Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Updates in CML: recent trials and novel agents

Susanne Saussele • 16 Apr 2018
BSH 2018
Chronic Myeloid Leukemia Leukemia Asciminib Dasatinib Imatinib Nilotinib Ponatinib
EURO-SKI

Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. Discussed are Phase I trial of the BCR-ABL inhibitor ABL001 (NCT02081378), and the use of ponatinib as a second line therapy. Prof. Saussele herself is working on the EURO-SKI trial (NCT01596114) in individuals with late relapse CML, partially assessing the effects of halting treatment with imatinib, nilotinib and dasatinib, and she holds promise for the upcoming results. This interview took place at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.

More from Susanne Saussele

The importance of better selecting patients with CML who are eligible for treatment discontinuation
1:10
The importance of better selecting patients with CML who are eligible for treatment discontinuation
Susanne Saussele • 22 Oct 2022
The impact of ACA in CML & the importance of monitoring these patients
0:40
The impact of ACA in CML & the importance of monitoring these patients
Susanne Saussele • 22 Oct 2022
Examples of challenging scenarios for TFR in CML & how to manage them
1:22
Examples of challenging scenarios for TFR in CML & how to manage them
Susanne Saussele • 22 Oct 2022
Antibody responses to COVID-19 vaccines in patients with hematological malignancies
4:40
Antibody responses to COVID-19 vaccines in patients with hematological malignancies
Susanne Saussele • 11 Dec 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals